Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Leukemia, Myeloid, Acute 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Myelodysplastic Syndromes 8Burkitt Lymphoma 5Myeloproliferative Disorders 4Primary Myelofibrosis 3Multiple Myeloma 3Lymphoma, Mantle-Cell 3Leukemia, Myelomonocytic, Chronic 3Leukemia, Biphenotypic, Acute 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Non-Hodgkin 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hodgkin Disease 2Ganglioneuroblastoma 2Thrombocythemia, Essential 1Smoldering Multiple Myeloma 1Polycythemia Vera 1Neuroblastoma 1Lymphoma, T-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Prolymphocytic 1Leukemia, Plasma Cell 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Accelerated Phase 1

Interventions

Dexamethasone 114daratumumab 68Lenalidomide 66Bortezomib 55pomalidomide 44carfilzomib 39Cyclophosphamide 33Specimen Handling 30Calcium Dobesilate 30Biopsy 27Magnetic Resonance Spectroscopy 24belantamab mafodotin 20isatuximab 19fludarabine 17talquetamab 16iberdomide 15Melphalan 15dexamethasone acetate 13dexamethasone 21-phosphate 13auricularum 13fludarabine phosphate 11selinexor 10elotuzumab 10tocilizumab 9X-Rays 8Nivolumab 8Sirolimus 7trametinib 6Whole-Body Irradiation 6Mycophenolic Acid 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Multiple Myeloma × Stem Cell Transplantation × 90 days × Clear all
NCT04579523 2026-06-04

²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma

Fred Hutchinson Cancer Center

Phase 1 Not yet recruiting
30 enrolled
Plasma cell

Multiple Myeloma

NCT00114101 2026-05-29

Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

National Cancer Institute (NCI)

Phase 3 Active not recruiting
460 enrolled 11 charts
Plasma cell

Smoldering Multiple Myeloma, Multiple Myeloma

NCT03477539 2026-05-05

Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma

Mayo Clinic

Phase 2 Completed
49 enrolled 15 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡